In the AI value chain, application-layer leaders like Palantir and ServiceNow may win long term as chip/cloud margins ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The AWS SDK for JavaScript v3 is a rewrite of v2 with some great new features. As with version 2, it enables you to easily work with Amazon Web Services, but has a modular architecture with a separate ...

The frontier model is a commodity. The companies winning are the ones that own distribution, and venture capital is paying up ...

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

Building a model capable of RSI would require automating a range of specialist tasks currently carried out by humans. At present data scientists work on the theory of AI and coders put it into ...

Even as leading AI providers like OpenAI and Anthropic battle over the compute to train and release ever larger, more powerful models, other labs are going in a different direction — pursuing the ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Abstract: Return-oriented programming (ROP) attacks pose a significant threat to the control-flow integrity (CFI) of Internet of Things (IoT) devices, which operate in resource-constrained ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...